TP53 and neoplasm: Head-to-head dose-finding in OCI-Ly19 xenografts, a TP53-wild, double-hit, germinal-center model that typifies high-risk clinical disease [21,22,23], reproduced the classic biphasic toxicity of free DOX (Figure 1): doses ≥ 2.5 mg kg−1 produced weight loss, whereas 1.25 mg kg−1 delivered maximal tumor control with tolerable weight loss, echoing historical observations in other GCB lymphoma [35].